On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

Get ready to rumble. In one corner, it’s President Donald Trump. In the other, it’s the pharmaceutical industry. | President ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Medtronic has teamed up with Star Jones to get women talking about heart health. The TV personality is lending her star power ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

Johnson & Johnson has generated evidence that the pace of oncology innovation is overwhelming physicians. | Johnson & Johnson ...